title: A myostatin inhibitor (propeptide-Fc) increases muscle mass and muscle fiber size in aged mice but does not increase bone density or bone strength.
abstract: Loss of muscle and bone mass with age are significant contributors to falls and fractures among the elderly. Myostatin deficiency is associated with increased muscle mass in mice, dogs, cows, sheep and humans, and mice lacking myostatin have been observed to show increased bone density in the limb, spine, and jaw. Transgenic overexpression of myostatin propeptide, which binds to and inhibits the active myostatin ligand, also increases muscle mass and bone density in mice. We therefore sought to test the hypothesis that in vivo inhibition of myostatin using an injectable myostatin propeptide (GDF8 propeptide-Fc) would increase both muscle mass and bone density in aged (24 mo) mice. Male mice were injected weekly (20 mg/kg body weight) with recombinant myostatin propeptide-Fc (PRO) or vehicle (VEH; saline) for four weeks. There was no difference in body weight between the two groups at the end of the treatment period, but PRO treatment significantly increased mass of the tibialis anterior muscle (+ 7%) and increased muscle fiber diameter of the extensor digitorum longus (+ 16%) and soleus (+ 6%) muscles compared to VEH treatment. Bone volume relative to total volume (BV/TV) of the femur calculated by microCT did not differ significantly between PRO- and VEH-treated mice, and ultimate force (Fu), stiffness (S), toughness (U) measured from three-point bending tests also did not differ significantly between groups. Histomorphometric assays also revealed no differences in bone formation or resorption in response to PRO treatment. These data suggest that while developmental perturbation of myostatin signaling through either gene knockout or transgenic inhibition may alter both muscle and bone mass in mice, pharmacological inhibition of myostatin in aged mice has a more pronounced effect on skeletal muscle than on bone.
authors.affiliation: Georgia Regents University, Augusta, GA 30912, USA.
authors.forename: Phonepasong
authors.initials: P
authors.lastname: Arounleut
authors.forename: Peter
authors.initials: P
authors.lastname: Bialek
authors.forename: Li-Fang
authors.initials: LF
authors.lastname: Liang
authors.forename: Sunil
authors.initials: S
authors.lastname: Upadhyay
authors.forename: Sadanand
authors.initials: S
authors.lastname: Fulzele
authors.forename: Maribeth
authors.initials: M
authors.lastname: Johnson
authors.forename: Mohammed
authors.initials: M
authors.lastname: Elsalanty
authors.forename: Carlos M
authors.initials: CM
authors.lastname: Isales
authors.forename: Mark W
authors.initials: MW
authors.lastname: Hamrick
mesh_terms: D000375:Aging / Q000473:pathology / Q000502:physiology; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D004353:Drug Evaluation, Preclinical / Q000379:methods; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018485:Muscle Fibers, Skeletal / Q000187:drug effects / Q000473:pathology; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000473:pathology; D055435:Myostatin / Q000037:antagonists & inhibitors / Q000172:deficiency / Q000494:pharmacology / Q000627:therapeutic use*; D010012:Osteogenesis / Q000187:drug effects / Q000502:physiology; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D055948:Sarcopenia / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D013314:Stress, Mechanical; D013977:Tibia / Q000187:drug effects / Q000503:physiopathology; D055114:X-Ray Microtomography / Q000379:methods
chemical_list: C525912:Mstn protein, mouse; D055435:Myostatin; D011994:Recombinant Proteins
keywords: Anabolic therapy; Fractures; GDF-8; Osteoporosis; Sarcopenia